Seres Therapeutics, Inc.
MCRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,582,761 | $3,584,084 | $12,104,629 | $763,885 |
| - Cash | $30,793 | $127,965 | $163,030 | $180,002 |
| + Debt | $91,640 | $213,936 | $162,590 | $49,211 |
| Enterprise Value | $2,643,608 | $3,670,055 | $12,104,189 | $633,094 |
| Revenue | $0 | $0 | $0 | $144,927 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$3,532 | $0 | $0 | $144,927 |
| % Margin | – | – | – | 100% |
| EBITDA | -$120,303 | -$181,419 | -$170,932 | -$56,721 |
| % Margin | – | – | – | -39.1% |
| Net Income | $136 | -$113,724 | -$250,157 | -$65,578 |
| % Margin | – | – | – | -45.2% |
| EPS Diluted | -18.864 | -17.769 | -46.292 | -14.302 |
| % Growth | -6.2% | 61.6% | -223.7% | – |
| Operating Cash Flow | -$148,609 | -$117,354 | -$228,816 | $6,688 |
| Capital Expenditures | -$380 | -$7,975 | -$9,821 | -$9,566 |
| Free Cash Flow | -$148,989 | -$125,329 | -$238,637 | -$2,878 |